- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6823
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictors of dopamine agonist resistance in prolactinoma patients ; volume:20 ; number:1 ; day:19 ; month:5 ; year:2020 ; pages:1-8 ; date:12.2020
BMC endocrine disorders ; 20, Heft 1 (19.5.2020), 1-8, 12.2020
- Creator
-
Vermeulen, Elle
D’Haens, Jean
Stadnik, Tadeusz
Unuane, David
Barbe, Kurt
Van Velthoven, Vera
Gläsker, Sven
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12902-020-0543-4
- URN
-
urn:nbn:de:101:1-2020072319473299376293
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vermeulen, Elle
- D’Haens, Jean
- Stadnik, Tadeusz
- Unuane, David
- Barbe, Kurt
- Van Velthoven, Vera
- Gläsker, Sven
- SpringerLink (Online service)
Other Objects (12)
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s disease
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s disease
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist